INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference

Core Insights - INmune Bio Inc. is a clinical-stage biotechnology company focused on inflammation and immunology through the innate immune system [1][2] - The company will present at the 2025 RBC Capital Markets Global Healthcare Conference on May 20-21, 2025 [1][2] Company Overview - INmune Bio Inc. is publicly traded on NASDAQ under the ticker INMB [2] - The company has three main product platforms: - Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, targeting Mild Alzheimer's disease, Mild Cognitive Impairment, and treatment-resistant depression [2] - Natural Killer Cell Priming Platform, featuring INKmune®, aimed at treating metastatic castration-resistant prostate cancer [2] - CORDStrom™, a proprietary platform using human umbilical cord-derived mesenchymal Stromal/Stem cells, recently completed trials for recessive dystrophic epidermolysis bullosa [2] - The company employs a precision medicine approach for diseases associated with chronic inflammation and cancer [2]